Endonovo Therapeutics, Inc. (ENDV)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 24.74 Million USD | -26.05% |
| 2022 | 33.46 Million USD | 88.18% |
| 2021 | 17.78 Million USD | 4.72% |
| 2020 | 16.98 Million USD | -28.59% |
| 2019 | 23.77 Million USD | 52.09% |
| 2018 | 15.63 Million USD | 10.39% |
| 2017 | 14.16 Million USD | 59.48% |
| 2016 | 8.88 Million USD | 15.85% |
| 2015 | 7.66 Million USD | 61.77% |
| 2014 | 4.73 Million USD | 12.67% |
| 2013 | 4.2 Million USD | 114.66% |
| 2012 | 1.95 Million USD | 151427.92% |
| 2011 | 1293.00 USD | -31.95% |
| 2010 | 1900.00 USD | 0.0% |
| 2009 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 25.79 Million USD | 2.05% |
| 2024 Q1 | 25.27 Million USD | 2.15% |
| 2023 Q3 | 23.77 Million USD | 2.41% |
| 2023 Q2 | 23.21 Million USD | -9.2% |
| 2023 Q4 | 24.74 Million USD | 4.08% |
| 2023 FY | 24.74 Million USD | -26.05% |
| 2023 Q1 | 25.56 Million USD | -23.59% |
| 2022 Q1 | 19.85 Million USD | 11.64% |
| 2022 FY | 33.46 Million USD | 88.18% |
| 2022 Q4 | 33.46 Million USD | 58.91% |
| 2022 Q3 | 21.05 Million USD | 1.46% |
| 2022 Q2 | 20.75 Million USD | 4.55% |
| 2021 Q4 | 17.78 Million USD | -12.64% |
| 2021 FY | 17.78 Million USD | 4.72% |
| 2021 Q2 | 19.25 Million USD | 4.13% |
| 2021 Q1 | 18.49 Million USD | 8.92% |
| 2021 Q3 | 20.35 Million USD | 5.69% |
| 2020 Q4 | 16.98 Million USD | 9.59% |
| 2020 Q1 | 14.2 Million USD | -40.25% |
| 2020 FY | 16.98 Million USD | -28.59% |
| 2020 Q2 | 15.07 Million USD | 6.12% |
| 2020 Q3 | 15.49 Million USD | 2.76% |
| 2019 Q2 | 20.36 Million USD | 32.35% |
| 2019 Q1 | 15.39 Million USD | -1.56% |
| 2019 FY | 23.77 Million USD | 52.09% |
| 2019 Q3 | 19.97 Million USD | -1.91% |
| 2019 Q4 | 23.77 Million USD | 19.01% |
| 2018 FY | 15.63 Million USD | 10.39% |
| 2018 Q4 | 15.63 Million USD | -16.81% |
| 2018 Q3 | 18.79 Million USD | 40.24% |
| 2018 Q2 | 13.4 Million USD | 2.34% |
| 2018 Q1 | 13.09 Million USD | -7.55% |
| 2017 Q1 | 13.42 Million USD | 51.17% |
| 2017 Q2 | 9.35 Million USD | -30.3% |
| 2017 Q3 | 13.34 Million USD | 42.61% |
| 2017 Q4 | 14.16 Million USD | 6.13% |
| 2017 FY | 14.16 Million USD | 59.48% |
| 2016 Q3 | 8.78 Million USD | 19.45% |
| 2016 FY | 8.88 Million USD | 15.85% |
| 2016 Q4 | 8.88 Million USD | 1.11% |
| 2016 Q2 | 7.35 Million USD | -20.83% |
| 2016 Q1 | 9.28 Million USD | 21.16% |
| 2015 Q3 | 5.99 Million USD | 9.9% |
| 2015 Q1 | 4.9 Million USD | 3.55% |
| 2015 FY | 7.66 Million USD | 61.77% |
| 2015 Q4 | 7.66 Million USD | 27.94% |
| 2015 Q2 | 5.45 Million USD | 11.1% |
| 2014 Q3 | 4.58 Million USD | -11.03% |
| 2014 FY | 4.73 Million USD | 12.67% |
| 2014 Q4 | 4.73 Million USD | 3.4% |
| 2014 Q1 | 4.94 Million USD | 17.46% |
| 2014 Q2 | 5.15 Million USD | 4.26% |
| 2013 Q4 | 4.2 Million USD | 19.25% |
| 2013 FY | 4.2 Million USD | 114.66% |
| 2013 Q1 | 2.49 Million USD | 27.19% |
| 2013 Q2 | 3.08 Million USD | 23.99% |
| 2013 Q3 | 3.52 Million USD | 14.15% |
| 2012 Q4 | 1.95 Million USD | -18.19% |
| 2012 FY | 1.95 Million USD | 151427.92% |
| 2012 Q1 | 1.74 Million USD | 22.95% |
| 2012 Q2 | 2.1 Million USD | 20.53% |
| 2012 Q3 | 2.39 Million USD | 13.81% |
| 2011 FY | 1293.00 USD | -31.95% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | 1.42 Million USD | 0.0% |
| 2010 FY | 1900.00 USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -90105.326% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -161.422% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 65.854% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -2959.62% |
| Rebus Holdings, Inc. | 5.24 Million USD | -372.072% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 58.068% |
| Qrons Inc. | 1.48 Million USD | -1562.243% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -1918.086% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 66.97% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -55265.194% |
| Skye Bioscience, Inc. | 14.07 Million USD | -75.85% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 53.577% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -158.255% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -5769.997% |
| SQZ Biotechnologies Company | 50.03 Million USD | 50.547% |
| Intellipharmaceutics International Inc. | 12 Million USD | -106.066% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -542.516% |
| Mesoblast Limited | 188.44 Million USD | 86.868% |
| Marizyme, Inc. | 26.67 Million USD | 7.234% |
| Genus plc | 485 Million USD | 94.898% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -323.543% |
| Pharming Group N.V. | 244.07 Million USD | 89.861% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -1131.066% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -883.418% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -551.211% |
| ContraFect Corporation | 32.53 Million USD | 23.931% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1148.974% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -546.507% |
| IMV Inc. | 37.93 Million USD | 34.764% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -110.1% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1529632.702% |
| ONE Bio Corp. | 27.49 Million USD | 10.001% |
| Accustem Sciences Inc. | 1.07 Million USD | -2192.914% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 68.035% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -1069.987% |
| Q BioMed Inc. | 8.13 Million USD | -204.269% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 70.162% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -380.876% |
| Biomind Labs Inc. | 1.49 Million USD | -1551.263% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 79.156% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -173.673% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -34.464% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1625.832% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -17315.129% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -12204.355% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -330.679% |
| GB Sciences, Inc. | 5.41 Million USD | -356.775% |
| Alpha Cognition Inc. | 7.16 Million USD | -245.385% |
| HST Global, Inc. | 593.59 Thousand USD | -4068.854% |
| CSL Limited | 18.62 Billion USD | 99.867% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -1865.229% |
| Halberd Corporation | 728.71 Thousand USD | -3295.826% |
| Enzolytics Inc. | 365.26 Million USD | 93.225% |
| Agentix Corp. | 2.51 Million USD | -885.68% |
| Resverlogix Corp. | 67.39 Million USD | 63.283% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -2850.409% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 94.438% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1343.759% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -107.896% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -575.168% |
| AVAX Technologies, Inc. | 3.99 Million USD | -519.62% |
| Zenith Capital Corp. | 27.56 Thousand USD | -89660.336% |
| Genscript Biotech Corporation | 1.32 Billion USD | 98.134% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -10268.997% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -562.667% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -3534.664% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -812.585% |
| Kadimastem Ltd | 3.5 Million USD | -606.048% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -36873.55% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 50.768% |
| BioStem Technologies, Inc. | 15.9 Million USD | -55.59% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -5225.173% |
| LadRx Corporation | 2.2 Million USD | -1024.55% |
| Cell Source, Inc. | 15.8 Million USD | -56.554% |
| Regen BioPharma, Inc. | 5.45 Million USD | -353.422% |
| Regen BioPharma, Inc. | 5.45 Million USD | -353.422% |
| NovAccess Global Inc. | 7.86 Million USD | -214.806% |
| Affymax, Inc. | 8.87 Million USD | -178.954% |
| Itoco Inc. | 1.65 Million USD | -1396.901% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -1106.202% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -309.093% |
| Mobile Lads Corp. | 1.31 Million USD | -1783.98% |
| CytoDyn Inc. | 127.89 Million USD | 80.651% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -59102.438% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1479.826% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -124.041% |
| SYBLEU INC | 681.41 Thousand USD | -3531.575% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -305.546% |
| International Stem Cell Corporation | 5.27 Million USD | -368.941% |
| Bioxytran, Inc. | 3.24 Million USD | -661.533% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -3854.246% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -435.962% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 39.638% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -11.143% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -1121.793% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -351.735% |
| Neutra Corp. | 973.52 Thousand USD | -2441.889% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 14.713% |
| PureTech Health plc | 125.58 Million USD | 80.295% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -558.643% |
| IXICO plc | 1.9 Million USD | -1202.222% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -20.542% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 76.05% |
| CSL Limited | 18.62 Billion USD | 99.867% |
| Cellectis S.A. | 249.36 Million USD | 90.077% |